Achilles Therapeutics Plc (ACHL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Achilles Therapeutics Plc announced strong financial results for Q1 2024, with a cash reserve of $112.3 million, extending their operational runway through 2025. The company reported interim Phase I/IIa data on T cell therapies for advanced cancers, noting improvements and anticipating further data in the latter half of 2024. Research and development expenses decreased, contributing to a smaller net loss compared to the previous year.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.